CN109996812A - 用于诊断和治疗重症肌无力的肽及其用途 - Google Patents

用于诊断和治疗重症肌无力的肽及其用途 Download PDF

Info

Publication number
CN109996812A
CN109996812A CN201780064528.7A CN201780064528A CN109996812A CN 109996812 A CN109996812 A CN 109996812A CN 201780064528 A CN201780064528 A CN 201780064528A CN 109996812 A CN109996812 A CN 109996812A
Authority
CN
China
Prior art keywords
peptide
amino acid
seq
peptides
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780064528.7A
Other languages
English (en)
Chinese (zh)
Inventor
罗伯特·H·费尔克劳
沃·B·特林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California San Diego UCSD
Original Assignee
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California San Diego UCSD filed Critical University of California San Diego UCSD
Publication of CN109996812A publication Critical patent/CN109996812A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/6857—Antibody fragments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Rehabilitation Therapy (AREA)
CN201780064528.7A 2016-09-08 2017-09-07 用于诊断和治疗重症肌无力的肽及其用途 Pending CN109996812A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662384896P 2016-09-08 2016-09-08
US62/384,896 2016-09-08
PCT/US2017/050521 WO2018049053A2 (en) 2016-09-08 2017-09-07 Peptides and uses thereof for diagnosing and treating myasthenia gravis

Publications (1)

Publication Number Publication Date
CN109996812A true CN109996812A (zh) 2019-07-09

Family

ID=61562129

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780064528.7A Pending CN109996812A (zh) 2016-09-08 2017-09-07 用于诊断和治疗重症肌无力的肽及其用途

Country Status (8)

Country Link
US (1) US11422132B2 (https=)
EP (1) EP3512873B1 (https=)
JP (1) JP7169267B2 (https=)
KR (1) KR102501179B1 (https=)
CN (1) CN109996812A (https=)
AU (1) AU2017322312B2 (https=)
CA (1) CA3036130A1 (https=)
WO (1) WO2018049053A2 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7169267B2 (ja) 2016-09-08 2022-11-10 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 重症筋無力症を診断および治療するためのペプチドおよびその使用
EP3715374A1 (en) 2019-03-23 2020-09-30 Ablevia biotech GmbH Compound for the sequestration of undesirable antibodies in a patient
US11986536B2 (en) 2019-03-23 2024-05-21 Ablevia Biotech Gmbh Compound for the sequestration of undesirable antibodies in a patient
CN121204097A (zh) * 2019-05-13 2025-12-26 宾夕法尼亚大学董事会 乙酰胆碱受体嵌合自身抗体受体细胞的组合物和方法
US12606631B2 (en) 2020-05-20 2026-04-21 Remd Biotherapeutics Inc Antibodies which bind human endothelin receptor a (ETAR)
CN112029880B (zh) * 2020-09-15 2023-04-28 石家庄市人民医院(石家庄市第一医院、石家庄市肿瘤医院、河北省重症肌无力医院、石家庄市心血管病医院) 用于重症肌无力的检测的微生物及应用
EP4217401A1 (en) 2020-09-24 2023-08-02 Ablevia biotech GmbH Compound for the prevention or treatment of myasthenia gravis

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020081652A1 (en) * 1997-05-07 2002-06-27 Sara Fuchs Recombinant fragments of the human acetylcholine receptor and their use for treatment of myasthenia gravis
CN1432024A (zh) * 2000-03-31 2003-07-23 科里克萨公司 识别潜在的免疫优势乙酰胆碱受体α亚基肽
US20110237688A1 (en) * 2008-07-29 2011-09-29 The Board Of Regents Of The University Of Texas System Methods and compositions related to acetylocholine receptor conjugates

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3391831B2 (ja) * 1993-01-13 2003-03-31 株式会社クラレ 環状ペプチド
AU780460B2 (en) 1999-09-15 2005-03-24 Janssen Pharmaceutica N.V. Nicotinic acetylcholine receptor alpha10 subunit
JP4283812B2 (ja) 2006-01-06 2009-06-24 財団法人工業技術研究院 重症筋無力症の診断方法およびそのキット
JP4495776B1 (ja) 2009-07-30 2010-07-07 日本製薬株式会社 融合蛋白質
JP7169267B2 (ja) 2016-09-08 2022-11-10 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 重症筋無力症を診断および治療するためのペプチドおよびその使用

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020081652A1 (en) * 1997-05-07 2002-06-27 Sara Fuchs Recombinant fragments of the human acetylcholine receptor and their use for treatment of myasthenia gravis
CN1432024A (zh) * 2000-03-31 2003-07-23 科里克萨公司 识别潜在的免疫优势乙酰胆碱受体α亚基肽
US20110237688A1 (en) * 2008-07-29 2011-09-29 The Board Of Regents Of The University Of Texas System Methods and compositions related to acetylocholine receptor conjugates

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
VU B. TRINHA等: "《Design, synthesis, and characterization of a 39 amino acid peptidemimic of the main immunogenic region of the Torpedo acetylcholinereceptor》", 《MOLECULAR IMMUNOLOGY》 *
VU BAO TRINH: "《THERAPEUTIC PEPTIDE MIMICS OF THE ACETYLCHOLINE RECEPTOR MAIN IMMUNOGENIC REGION FOR TREATING MYASTHENIA GRAVIS》", 《PH.D.THESIS.UNIVERSIGY OF CALIFORNIA》 *

Also Published As

Publication number Publication date
US11422132B2 (en) 2022-08-23
WO2018049053A2 (en) 2018-03-15
EP3512873B1 (en) 2023-11-01
JP7169267B2 (ja) 2022-11-10
KR20190045323A (ko) 2019-05-02
AU2017322312B2 (en) 2021-10-28
EP3512873A4 (en) 2020-03-18
EP3512873C0 (en) 2023-11-01
CA3036130A1 (en) 2018-03-15
WO2018049053A3 (en) 2018-05-17
EP3512873A2 (en) 2019-07-24
JP2019531716A (ja) 2019-11-07
AU2017322312A1 (en) 2019-03-28
KR102501179B1 (ko) 2023-02-16
US20200033338A1 (en) 2020-01-30

Similar Documents

Publication Publication Date Title
US11422132B2 (en) Peptides and uses thereof for diagnosing and treating myasthenia gravis
CN115244077B (zh) 蛋白质治疗剂
Hu et al. Molecular and functional characterization of the p62 complex, an assembly of nuclear pore complex glycoproteins.
US20200071363A1 (en) Animal model of a mood disorder and screening method
CN101825637A (zh) 用于免疫诊断1型糖尿病的组合物
CN104640877A (zh) 用于检测自身免疫性疾病的诊断方法和相关主题
CA2832391C (en) Means and methods for diagnosing and treating multiple sclerosis
US8552152B2 (en) Compositions and methods for modulating dopamine neurotransmission
AU2016281649B2 (en) Antigenic peptides and uses thereof for diagnosing and treating autism
CN106456700B (zh) 糖尿病治疗和预防的新靶标
JP7326108B2 (ja) 自己免疫性水疱症の診断
US20120039919A1 (en) Diabetes diagnostic, prophylactic, and therapeutic compositions and methods
US20220324913A1 (en) Antigenic neuron specific enolase peptides for diagnosing and treating autism
CN121620380A (zh) 治疗方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20190709

WD01 Invention patent application deemed withdrawn after publication